37 to 2
We extracted data
The current meta-analysis showed that olanzapine was statistically and clinically superior to non-olanzapine regimen in preventing CINV in most domains of the parameters
98, 95% CI 1
After 1 week of treatment, the reduction in nausea scores in the olanzapine arm was 8 points (95% CI, 7-8) higher than that of the placebo arm (P <
The present four-drug combination therapy containing olanzapine 5 mg sufficiently controls nausea and vomiting at a lower dose compared with the olanzapine
2014;22:1143-1151
Olanzapine 5 mg per day should be recommended as the initial dose because of
increased blinking or spasms of the eyelid
00, which is 97% off the average retail price of $178
Olanzapine is also approved for use with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), in patients with Only two RCTs administered olanzapine for nausea and vomiting, for more than five days (Navari 2010b; The findings of this Cochrane systematic review of olanzapine for the prevention and treatment of nausea and vomiting in adults are in keeping with all nine independent systematic reviews and meta‐analyses on the topic
RR 1
Although they are effective in controlling voices and delusions for many people with schizophrenia, they have a smaller effect on symptoms such as apathy and social
It is suggested that standard adult oral doses of olanzapine for schizophrenia are: 2
Pharmacology
It has structural and pharmacological properties resembling those of the atypical antipsychotic clozapine and an improved tolerability profile compared with the classical antipsychotic haloperidol
There are 650 drugs known to interact with olanzapine, along with 19 disease interactions, and 4 alcohol/food interactions
The binding for 5HT3 and dopamine-2 receptors account for its antiemetic benefit
If any of Common side effects of olanzapine
Olanzapine is an efficacious and well-tolerated atypical antipsychotic indicated for the treatment of schizophrenia and acute manic or mixed episodes, along with maintenance therapy in bipolar disorder and (in some countries) related psychiatric disorders
Main Outcomes and MeasuresPatient-reported outcomes were used for study end points
Cochrane Review Group funding acknowledgement: the National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Pain, Palliative and Supportive Care Review Group (PaPaS)